Navigation Links
Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
Date:10/24/2007

lixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation statements related to the future development and potential efficacy of XL647. Words such as "believe," "suggest," "may," "anticipates," "should," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the lengthy, costly and uncertain process of clinical testing of XL647 and Exelixis' other compounds and the potential failure of XL647 and Exelixis' other compounds to demonstrate safety and efficacy in clinical testing. These and other risk factors are discussed under "Risk Factors" and elsewhere in Exelixis' quarterly report on Form 10-Q for the quarter ended June 30, 2007 and other filings with the Securities and Exchange Co
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Research and Markets has announced ... Markets" report to their offering. ... - including products to treat cancer, diabetes, HIV/AIDS and ... the final stages of clinical drug testing for new ... production capital to upscale while anticipating FDA or EMA ...
(Date:9/23/2014)... -- SiteOne Therapeutics Inc. today announced the completion of its ... Management and Biobrit LLC, with additional investors Mission Bay ... financing positions SiteOne to advance its oral Na V ... its technology platform for long-acting local analgesics, pain diagnostics ... the financing, Lowell Sears (Sears Capital Management) ...
(Date:9/23/2014)... Sept. 23, 2014   COTA, Inc. today ... $7 million Series A funding round led by Horizon ... is the first big data platform designed by practicing ... analysis for cancer care in support of healthcare,s new ... to expand development of the COTA platform, hire biostatisticians, ...
Breaking Medicine Technology:Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
... Inc. (NTI(R)) (Nasdaq: NTII ), today announced ... monitoring board (DSMB) has,recommended continuation of the company,s ... brief intravenous infusion of Viprinex(TM) (ancrod),started within 6 ... 3,months. This is the fifth DSMB meeting for ...
... Genmab has,announced that HuMax-EGFr (zalutumumab) inhibits epidermal ... factor receptor (EGFr),molecules into a very compact, ... central to its role in signaling, and ... of cancer cell growth., Genmab A/S ...
Cached Medicine Technology:Fifth DSMB Meeting Supports Neurobiological Technologies' Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod) 2Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS 2Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS 3
(Date:9/23/2014)... (PRWEB) September 23, 2014 "The primary purpose ... control," said an inventor from Sacramento, Ca.. "Call lights are ... or left hanging on the IV pole out of the ... the nurse call device whenever they need it, I created ... effectively position the nurse call device within easy reach. The ...
(Date:9/23/2014)... Savannah, GA (PRWEB) September 23, 2014 ... local community through philanthropic support. Most recently, the gym ... through their Ageless Fitness program. Throughout the year, World ... for many other charitable causes. , Over the summer, ... Meals on Wheels. Through their Ageless Fitness program, participants ...
(Date:9/23/2014)... Dr. Connie Casad has announced that she ... office space at 12200 Park Central Drive, Suite 200, Dallas, ... be Park Cities Aesthetics, Optimal Health and Wellness, her gynecology ... move, Dr. Casad said, “The patients’ comfort and satisfaction are ... want them to always feel like their needs are valued ...
(Date:9/23/2014)... News) -- Both drinking and getting drunk at an ... by high school students, a new study suggests. ... students who drink, could help expand alcohol-prevention efforts aimed ... stop them from becoming binge drinkers, the researchers suggested. ... alcohol use and progression to first heavy use as ...
(Date:9/23/2014)... Grinnell Mutual seeks submissions from the ... Midwest. Working Together Making It Better will provide ... projects positively impacting their communities. , “So many ... communities a better places,” said Grinnell Mutual ... Baker. “Their leadership—as coaches, as volunteers, as mentors—help ...
Breaking Medicine News(10 mins):Health News:World of Home Fitness Supports Meals on Wheels 2Health News:Dr. Connie Casad Moving to New Office Location 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 3Health News:Grinnell Mutual Invites Submissions for Innovative, Collaborative Local Projects in Its Second Annual Working Together Making It Better Promotion 2
... Number of AIDS-Related Deaths Continued to Decline, WASHINGTON, ... who were HIV infected or had confirmed AIDS on ... the end of 2004, the Justice,Department,s Bureau of Justice ... consecutive year the number has fallen. In 1999 there,were ...
... SAN DIEGO, Sept. 27 NuVasive, Inc. (Nasdaq:,NUVA), a ... surgical treatments for the spine, announced today,details relating to ... on Wednesday, October 24, 2007, after the close of ... Wednesday, October 24, 2007 at,5:00 p.m. ET / 4:00 ...
... in preparation for partnering, CARLSBAD, Calif., Sept. ... today announced its purchase of all,of the equity ... $120,million. Prompting this transaction, on September 13, 2007, ... a,Johnson & Johnson company, to discover, develop and ...
... Calif., Sept. 27 The following was ... A new "study" released Wednesday by Death ... group) board member Margaret Peggy Battin,attempts to ... "disproportionately",impacted by assisted suicide legalization in Oregon ...
... For Humanity Continued By Binson,s Home ... Family Presented With New Home Saturday, September 22nd On Detroit,s East ... ... able to,enjoy a fresh start with a new home thanks in part to the ...
... Care,Management Association (PCMA) issued the following response to ... "PCMA member companies have routinely paid clean ... doing so. Before rushing to judgment,on the issue ... conduct an,independent study to explore this issue generally ...
Cached Medicine News:Health News:HIV/AIDS Cases Among State and Federal Prison Inmates Fell for the Sixth Straight Year During 2005 2Health News:HIV/AIDS Cases Among State and Federal Prison Inmates Fell for the Sixth Straight Year During 2005 3Health News:NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results 2Health News:NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results 3Health News:Isis Acquires Symphony GenIsis 2Health News:Isis Acquires Symphony GenIsis 3Health News:Californians Against Assisted Suicide: Assisted Suicide 'Study' From Biased Author is Questionable at Best 2Health News:Donation of $15,000 and Hard Work Allows a Family in Need to Move into New Home 2
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
...
Medicine Products: